Table 2.

Post-treatment values for IMT, FMD and ASCVD risk (and values related to its computation).

Variable	Home-based (n = 53)	Supervised (n = 51)	Sertraline (n = 49)	Placebo (n = 49)	Active vs. Placebo	Exercise vs. Sertraline
Intima Medial Thickness, mm *	0.65 (0.01)	0.64 (0.01)	0.63 (0.01)	0.67 (0.01)	.037	.291
Flow-Mediated Dilation, % *	5.8 (0.5)	6.9 (0.6)	6.2 (0.6)	4.8 (0.6)	.032	.798
ASCVD Risk Score, 10-year % Risk (ranked) *	4.6 (0.3)	4.0 (0.3)	4.0 (0.3)	4.3 (0.3)	.049	.741
Systolic Blood Pressure, mm Hg*	122 (2)	118 (2)	117 (2)	124 (2)	.012	.245
Total Cholesterol, ng/ml	209 (4)	204 (4)	215 (4)	203 (4)	.134	.047
High Density Lipoprotein, ng/ml	55 (1)	57 (1)	55 (1)	56 (1)	.894	.534

Analyses are adjusted for age, sex, severity of depression, and the respective pretreatment level of each outcome. FMD analyses were also adjusted for baseline arterial diameter.

^*Active treatments differ from Placebo at P < .05. Values are derived from multiple imputation estimates based on the entire sample (n = 202). Complete data were available for 169 participants for the ASCVD risk score and its components (84%), 172 participants for flow-mediated dilation analyses (85%), and 168 for intima medial thickness analyses (83%).